Related Experiment Video
Updated: Jun 12, 2026

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations
Jennifer A Belsky1, Jamie Shoag2, Paul D Harker-Murray3
1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA; Division of Pediatric Hematology/Oncology, Riley Hospital for Children, Indianapolis, IN, USA.
Abstract:
Advances in pediatric and adolescent young adult Hodgkin lymphoma (HL), including the incorporation of targeted therapy and immunotherapy have resulted in excellent cure rates with survival greater than 90%, including patients with advanced stage disease. Current trials seek to maintain excellent survival while reducing acute and long-term toxicities. Despite these successes, vulnerable patient populations, including Black, Hispanic, and adolescent young adult patients, continue to have inferior outcomes. This article reviews recent therapeutic advances in HL, summarizes therapeutic gaps, and highlights opportunities to improve outcomes in patients with social and economic disparities.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Treatment Resistent Cancers
Treatment Resistant Cancers
Pharmacokinetics in Pediatric Patients: Drug Metabolism
